Andrzej Szczudlik

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

Determination of nitrite/nitrate in human biological material by the simple Griess reaction

Ibeth Guevara, J. Iwanejko, A. Dembińska-Kieć et al. · Clinica Chimica Acta · 1998 · 647 citations

Natural Sciences, Biochemistry, Chemistry +2

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion

J.-M. Lee, E.M. Ramos, J.-H. Lee et al. · Neurology · 2012 · 391 citations · Full text

Life Sciences, Genetics, Neurology +15

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Davina J. Hensman Moss, Antonio F. Pardiñas, Douglas R. Langbehn et al. · The Lancet Neurology · 2017 · 332 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard, Vera Bril, Ted M. Burns et al. · Neurology · 2019 · 288 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14